XCancer

Predictive Value of Tumor Microenvironment PET/CT for Response and Prognosis in Aggressive Lymphoma: A Multicenter Study

Description:

This multicenter study aims to evaluate the predictive value of tumor microenvironment PET/CT imaging for treatment response and prognosis in patients with aggressive lymphoma. Eligible patients with histologically confirmed aggressive lymphoma will undergo FAPI PET/CT imaging, and selected patients who are candidates for immunotherapy will undergo Grazytracer PET/CT imaging. These imaging methods are intended to assess fibroblast activation protein expression and granzyme B activity in lymphoma lesions, reflecting cancer-associated fibroblasts and cytotoxic T-cell activity in the tumor microenvironment. The study will explore optimal imaging assessment criteria and develop clinical-pathological-imaging models to predict treatment response, prognosis, and the relationship between tumor heterogeneity and refractory or relapsed disease.

Sponsor:

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase:

N/A

Contacts:

Xuejuan Wang, M.D. (STUDY_CHAIR)

Xin Liu, M.D. (CONTACT)

liux0077@163.com

15621479631

Government Study Link:

NCT07657494 - Click here to see study on

ClinicalTrials.gov

NOTA-FAPI

Isotope(s):
Target(s):
  • FAP
Ligand Class: Small Molecules
Chelator: NOTA

NOTA-grazytracer

Isotope(s):
Target(s):
  • Granzyme B
Ligand Class: Small Molecules
Chelator: NOTA
Inclusion
  • Expected survival of at least 6 months and ability to complete follow-up.
  • * Histologically confirmed aggressive lymphoma.
  • No significant cardiac, hepatic, or renal dysfunction.
  • No previous history of malignant tumors.
  • Baseline PET/CT showing moderate to high FDG uptake in lymphoma lesions.
Exclusion
  • Active or uncontrolled chronic inflammation or infection.
  • Uncontrolled diabetes mellitus.
  • Lymphoma lesions have been surgically removed, with no positive lesions available for evaluation.
  • Incomplete clinical data or loss to follow-up.
  • * Low FDG uptake on baseline PET/CT.